FP802 dihydrochloride
Based on 1 Customer Validation
FP802 dihydrochloride is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 dihydrochloride exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology. FP802 dihydrochloride stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 dihydrochloride can be used for AD and ALS research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.84%
- CAS No.: 2490401-57-3
- Formule: C11H19Cl3N2
- Masse moléculaire:285.64
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mechanoreceptors Compound Library
HY-L095
-
Antidepressant Compound Library
HY-L108
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Voir tous les produits spécifiques à Isoform iGluR
More
Activité biologique
FP802 (8 μM, 24-72 h) hydrochloride disrupts the NMDAR/TRPM4 complex and provides neuroprotection in cellular models, without directly affecting neurite outgrowth[1].
FP802 (10 μM, 30 min) hydrochloride exhibits potent neuroprotection against glutamate (20 μM)-mediated toxicity (IC50 = 8.7 µM) and restores NMDA-suppressed immediate-early gene expression to physiological levels[2].
FP802 hydrochloride shows no antagonistic activity against NMDARs in HEK293 cells (IC50 > 250 μM for both, GluN1/GluN2A and GluN1/GluN2B)[2].
FP802 (30 min) hydrochloride dose-dependently blocks NMDA-induced death of post-mitotic neurons in forebrain organoids derived from sporadic ALS patient induced pluripotent stem cells (iPSCs)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mouse cortical neurons
-
Concentration:10 μM
-
Incubation Time:30 min
-
Result:Eliminated the transcriptional shut-off induced by eNMDARs and boosted the NMDA bath application-induced expression of the immediate-early genes (IEGs) Atf3, Arc, Bdnf, cFos, Inhibin beta A, and Npas4 to reach levels that were comparable to those achieved by Bicuculline (HY-N0219)-induced action potential bursting.
FP802 (40 mg/kg, s.c., daily from ~week 15 for 4 weeks) dihydrochloride safely halts motor neuron degeneration and extends survival in ALS mice by targeting the NMDAR/TRPM4 complex[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5xFAD transgenic mice and wild-type littermates[1]
-
Dosage:10 and 40 mg/kg
-
Administration:p.o., daily for 4 months
-
Result:Showed no apparent adverse effects on the liver, kidney, or heart.
Reduced the complex formation of GluN2B with TRPM4 in the 5xFAD mice at both 10 and 40 mg/kg.
Reduced complex formation of GluN2A with TRPM4 at 40 mg/kg.
Significantly decreased the interaction between NMDAR and TRPM4 without affecting the total protein levels of GluN2A, GluN2B, or TRPM4.
Led to a significant increase in the time 5xFAD mice spent in the target quadrant and the frequency with which they crossed the platform's prior location at the dose of 40 mg/kg, compared to vehicle.
Increased the time 5xFAD mice spent exploring the novel object in the Novel Object Recognition (NOR) test and the displaced object in the Novel Location Recognition (NLR) test relative to vehicle treatment.
Prevented the shift of mitochondrial morphologies from normal to pathological phenotypes in both CA1 and CA3.
Effectively preserved dendritic trees in 5xFAD mice as compared to controls, as demonstrated by increased total dendritic length and numbers of crossings in the Sholl analysis.
Prevented the increase in the density of 'apparent orphaned synapses' in both stratum oriens (CA1 basal dendrites) and stratum radiatum (CA1 apical dendrites) of 5xFAD mice.
Prevented the loss of excitatory and inhibitory synapses and the associated structural deterioration of postsynaptic densities (PSD) in the basal and apical dendrites of CA1 neurons, thereby preserving synaptic integrity in 5xFAD mice.
Led to a 25-40% reduction in Aβ plaque load, significantly limiting plaque development without completely preventing its formation.
-
Animal Model:Male SOD1G93A transgenic mice and wild-type littermates[2]
-
Dosage:40 mg/kg
-
Administration:s.c., daily from ~week 15 for 4 weeks
-
Result:Disrupted he interaction of TRPM4 with the NMDAR subunit GluN2B in mice spinal cord.
Significantly better neurological scores and less body weight loss than vehicle-treated controls.
Significantly improved motor performance (increased total distance traveled and rearing frequency in the open field).
Significantly extended the lifespan of SOD1G93A mice (survival median increased from 151 to 164 days).
Preserved larger soma sizes of lumbar spinal motor neurons compared to the control group at week 19.
Significantly reduced serum NfL levels while showing no effect on spinal microglial response or EAAT2 expression.
Showed no adverse effects on liver, kidney, heart, or blood counts.
Chemical Information
-
CAS No. 2490401-57-3
-
Appearance Solid
-
Masse moléculaire 285.64
-
Formule C11H19Cl3N2
-
Color White to off-white
-
SMILES
CCN(CC1=CC(Cl)=CC=C1)CCN.Cl.Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
H2O : 116.67 mg/mL (408.45 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yan J, et al. The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer's disease. Mol Psychiatry. 2025 Aug 26. [Content Brief]
[2]. Yan J, et al. TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS. Cell Rep Med. 2024 Feb 20;5(2):101413. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.5009 mL | 17.5046 mL | 35.0091 mL | 87.5228 mL |
| 5 mM | 0.7002 mL | 3.5009 mL | 7.0018 mL | 17.5046 mL | |
| 10 mM | 0.3501 mL | 1.7505 mL | 3.5009 mL | 8.7523 mL | |
| 15 mM | 0.2334 mL | 1.1670 mL | 2.3339 mL | 5.8349 mL | |
| 20 mM | 0.1750 mL | 0.8752 mL | 1.7505 mL | 4.3761 mL | |
| 25 mM | 0.1400 mL | 0.7002 mL | 1.4004 mL | 3.5009 mL | |
| 30 mM | 0.1167 mL | 0.5835 mL | 1.1670 mL | 2.9174 mL | |
| 40 mM | 0.0875 mL | 0.4376 mL | 0.8752 mL | 2.1881 mL | |
| 50 mM | 0.0700 mL | 0.3501 mL | 0.7002 mL | 1.7505 mL | |
| 60 mM | 0.0583 mL | 0.2917 mL | 0.5835 mL | 1.4587 mL | |
| 80 mM | 0.0438 mL | 0.2188 mL | 0.4376 mL | 1.0940 mL | |
| 100 mM | 0.0350 mL | 0.1750 mL | 0.3501 mL | 0.8752 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
FP802 dihydrochloride Related Classifications
HY-W611371A Related Classifications
Powered by Bioz